Overview

Sitaxsentan Efficacy And Safety Trial With A Randomized Prospective Assessment Of Adding Sildenafil (SR-PAAS)

Status:
Terminated
Trial end date:
2011-03-01
Target enrollment:
Participant gender:
Summary
This protocol is for subjects with pulmonary arterial hypertension and is the first of 3 studies forming the Sitaxsentan efficacy and safety trial with Randomized Prospective Assessment of Adding Sildenafil (SR-PAAS) program.
Phase:
Phase 3
Details
Lead Sponsor:
Pfizer
Treatments:
Endothelin Receptor Antagonists
Sitaxsentan